Divis Laboratories Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xs1mwbei6d5ugaum53fx352q.pdf

Key Takeaways


Custom Synthesis: Pipeline & GLP-1

Dr. Kiran S. Divi: "We make our own resins. We make our own building blocks. Okay. We make our own protected amino acids. And that's why we have a much more edge over working over others. So I would say in this GLP-1 right now the way things are looking, sky is the limit."

Generic Business: Volume Strength, Price Weakness

Nilima Prasad Divi: "If I'm looking at the volume base, there is double-digit growth. We still hold a substantial market share in some of our products, where we are one of the -- either number one, number two or number three manufacturer in the world. We haven't lost business. We haven't reduced our production. We haven't lost our customers. It's just that because of pricing pressure, the number is not looking great."

Kakinada Unit 3: Phase I Goes Live


Margins & Cost Structure

Dr. Kiran S. Divi: "A lot of things have changed in terms of the regulatory landscape, the cost of regulatory landscape, the cost of GMP requirements for what it was 10 to 15 years ago to what it is now. For a product launch, what used to be the cost to what it is today, it's a complete separate -- we have to look at it like a cost structure itself to understand the product viability and everything."

Contrast Media, Nutraceuticals & Other Verticals


Guidance & Commitments

CommitmentSpecificsTimeline
Kakinada Phase I completionRest of Phase I operationalAbout 6 months
Nutraceutical results visibilityResults from Nutraceutical effortsComing 6 months
Unit 1 & 2 capacity fill clarityPipeline projects filling freed-up capacityNext quarter
Double-digit revenue growth targetConservative yearly target, not quarter-specificOn a yearly basis
Generic vs custom synthesis balanceWishful thinking to reach 50/50 splitNo timeline (ongoing effort)

Key Metrics

MetricQ3 FY25
Consolidated total income₹2,401 cr, vs ₹1,915 cr in Q3 FY24
Profit before tax₹726 cr, vs ₹489 cr in Q3 FY24
Profit after tax₹589 cr, vs ₹358 cr in Q3 FY24
EBITDA margin32%, product-mix driven; no one-off cited
Gross margin60%, benefited from segmental mix
Material consumption40% of sales revenue, 9M FY25
Constant currency growth (9M)22%, vs negative 10% in 9M FY24
Product mix: generics vs custom synthesis47% generics, 53% custom synthesis
Nutraceutical revenue₹170 cr
Exports share87% of total sales revenue, 9M FY25
Exports to Europe and U.S.72% of total sales revenue, 9M FY25
Forex gain (9M)₹38 cr, vs ₹32 cr in 9M FY24
Capacity utilization (Unit 1 and Unit 2)80%
Kakinada project total spend (till Dec 31, 2024)₹1,340 cr, including assets capitalized
Capital work in progress₹1,157 cr, of which Kakinada is ₹745 cr
Cash on books₹3,659 cr as of Dec 31, 2024
Effective tax rate guidance25%, new regime adopted from FY25